WallStreetZenWallStreetZen

NASDAQ: ECOR
Electrocore Inc Stock Forecast, Predictions & Price Target

Analyst price target for ECOR

Based on 1 analyst offering 12 month price targets for Electrocore Inc.
Min Forecast
$15.00+165.02%
Avg Forecast
$15.00+165.02%
Max Forecast
$15.00+165.02%

Should I buy or sell ECOR stock?

Based on 1 analyst offering ratings for Electrocore Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ECOR stock forecasts and price targets.

ECOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-14

1 of 1

Forecast return on equity

Is ECOR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.5%

Forecast return on assets

Is ECOR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ECOR revenue forecast

What is ECOR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$25.1M+56.8%
Avg 2 year Forecast
$37.6M+134.59%
Avg 3 year Forecast
$49.8M+210.92%
ECOR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ECOR revenue growth forecast

How is ECOR forecast to perform vs Medical Devices companies and vs the US market?
Company
45.95%
Industry
8.28%
Market
10.16%
ECOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ECOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ECOR vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
ECOR$5.66$15.00+165.02%Buy
MODD$1.57$5.00+218.47%Buy
LUCD$0.72$2.75+280.36%Strong Buy
CODX$1.15$2.50+117.39%Hold
MDAI$1.83$4.00+118.58%Strong Buy

Electrocore Stock Forecast FAQ

Is Electrocore Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ECOR) stock is to Buy ECOR stock.

Out of 1 analyst, 0 (0%) are recommending ECOR as a Strong Buy, 1 (100%) are recommending ECOR as a Buy, 0 (0%) are recommending ECOR as a Hold, 0 (0%) are recommending ECOR as a Sell, and 0 (0%) are recommending ECOR as a Strong Sell.

If you're new to stock investing, here's how to buy Electrocore stock.

What is ECOR's revenue growth forecast for 2024-2026?

(NASDAQ: ECOR) Electrocore's forecast annual revenue growth rate of 45.95% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Electrocore's revenue in 2024 is $16,030,000.On average, 2 Wall Street analysts forecast ECOR's revenue for 2024 to be $150,876,055, with the lowest ECOR revenue forecast at $150,065,700, and the highest ECOR revenue forecast at $151,686,410. On average, 2 Wall Street analysts forecast ECOR's revenue for 2025 to be $225,728,826, with the lowest ECOR revenue forecast at $217,895,396, and the highest ECOR revenue forecast at $233,562,255.

In 2026, ECOR is forecast to generate $299,170,980 in revenue, with the lowest revenue forecast at $294,669,009 and the highest revenue forecast at $303,672,951.

What is ECOR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ECOR) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of N/A.

What is ECOR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ECOR price target, the average ECOR price target is $15.00, with the highest ECOR stock price forecast at $15.00 and the lowest ECOR stock price forecast at $15.00.

The Wall Street analyst predicted that Electrocore's share price could reach $15.00 by Mar 14, 2025. The average Electrocore stock price prediction forecasts a potential upside of 165.02% from the current ECOR share price of $5.66.

What is ECOR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ECOR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.